Lamivir

Lamivudine, the active ingredient in Lamivir, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as an oral formulation for oral use. It treats human immunodeficiency virus (HIV) infection and chronic hepatitis B infection in adult patients.

GNH USA supplies Lamivir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine is used in the management of viral infections that involve reverse transcriptase activity.

HIV infection: reduces viral load and helps restore immune function. Chronic hepatitis B infection: suppresses HBV replication and decreases liver inflammation.

Lamivudine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Fatigue: general tiredness without exertion. - Diarrhea: loose stools, usually self‑limiting.

Serious or Rare Side Effects: - Lactic acidosis: rare metabolic disturbance requiring immediate medical attention. - Severe hepatotoxicity: marked liver enzyme elevation or failure. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating lamivudine therapy, clinicians should consider several safety measures.

Monitor liver function: perform baseline and periodic hepatic enzyme tests. Assess renal function: evaluate creatinine clearance for possible dose adjustment. Screen for hepatitis B co‑infection: identify risk of viral reactivation. Counsel on adherence: emphasize the importance of consistent daily dosing. Store at room temperature: keep in the original container, protect from moisture and light.

Lamivudine can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis. - Stavudine: heightened peripheral neuropathy risk. - Ribavirin: may exacerbate hemolytic anemia.

Moderate Interactions (Monitor Closely): - Efavirenz: possible reduction in lamivudine plasma levels. - Nevirapine: monitor liver enzymes for hepatotoxicity. - Alcohol: may increase liver toxicity risk.